NEW YORK, May 17 (GenomeWeb News) - Shares in CombiMatrix were up 6 percent, or $.13, at $2.29 in mid-afternoon trading after the company said EAI, a subsidiary of Science Applications International Corporation, will deploy its array-based influenza screening technology.
As GenomeWeb News reported today, CombiMatrix said the deal "gets our technology into the field and into the hands of people and groups standing watch on US soil," said CMBX's CEO Amit Kumar.